daratumumab,talquetamab,teclistamab
janssen,genmab
['mmsm', 'redirectt-1']
redirectt-1: tec and talq -93 pts enrolled
- 34 pts to at rp2d, median line of x: 4
-37.6% with emd
safety: feb neutropenia (12%)
- ae: crs (76%) all grades, 3.2% grade 3/4; - 5 icans events in 3 pts
- 6.5% deaths due to drug related ae- all infection related #mmsm #asco2023
Multiple Myeloma Specialist  at UTSW Harold C. Simmons Comprehensive Cancer Center | Montefiore  & Tufts Alum